News
Philip Morris International Inc. (PMI) Reports 2022 First-Quarter Results
Regulatory News:
Philip Morris International Inc. (NYSE: PM) today announces its 2022 first-quarter results. Growth rates presented in this press release on an organic basis reflect
US Foods Reports Preliminary First Quarter Fiscal Year 2022 Earnings
US Foods Holding Corp. (NYSE: USFD), one of the largest foodservice distributors in the United States, today announced preliminary first quarter fiscal year 2022 results1. The Company will announce
Form 8.3 - The Vanguard Group, Inc.: Stagecoach Group plc
Form 8.3 - The Vanguard Group, Inc.: Sanne Group plc
DGAP-Adhoc: ROY Asset Holding SE: Successful conclusion of a social plan and reconciliation of interests at Dekoramik Klingenberg GmbH
Form 8.3 - The Vanguard Group, Inc.: National Express Group plc
Form 8.3 - The Vanguard Group, Inc.: HomeServe plc
Form 8.3 - The Vanguard Group, Inc.: GXO Logistics, Inc.
Form 8.3 - The Vanguard Group, Inc.: Brewin Dolphin Holdings plc
Rights and Issues Investment Trust PLC: NAV-Net Asset Value(s)
Chelverton UK Dividend Trust plc: NAV-Net Asset Value(s)
DGAP-News: 2G Energy AG lifts Q1 new order intake to EUR 53.6 million (previous year: EUR 46.4 million)
DGAP-Adhoc: 2G Energy AG plans share split following a capital increase from company funds
DGAP-News: US-based energy company chooses USU to optimize software licenses
DGAP-Adhoc: InTiCa Systems AG: InTiCa Systems AG plans conversion into a European Company ('SE')
Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today the publication of a peer-reviewed article
DGAP-News: Hawesko Holding AG: Hawesko Group with strong results in 2021
INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for
Sensorion Will Participate in Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit Held Virtually on April 26, 2022
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Taiwan's biggest offshore wind farm generates first power
ABB: Q1 2022 Results
Ad hoc Announcement pursuant to Art. 53 Listing Rules of SIX Swiss Exchange
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2022042000609